Motilin vs Larazotide
Head-to-head comparison of Motilin (Motilin) and Larazotide (Larazotide acetate (AT-1001)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Motilin | Larazotide |
|---|---|---|
| Category | Gastrointestinal | Gastrointestinal |
| Full Name | Motilin | Larazotide acetate (AT-1001) |
| Molecular Weight | ~2.7 kDa | N/A |
| Half-Life | ~20 min | short; designed for local gut action |
| Amino Acids | 22 | 8 |
| Typical Dose | No standard approved dose; experimental use only | 0.5-4 mg TID (clinical studies) |
| Route | IV|SC | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 81 | 40 |
| Research Status | Endogenous | Clinical |
Motilin Benefits
- ✓migrating motor complex support
- ✓gastric emptying
- ✓small-bowel clearance
Larazotide Benefits
- ✓tight-junction-support
- ✓reduced-permeability
- ✓symptom-reduction
- ✓barrier-protection
Motilin Dosing
0.1–1 mg (experimental)|IV/SC
Larazotide Dosing
0.5-4 mg orally before meals in clinical trials|typically three times daily|short-course or chronic study protocols
Motilin Side Effects
- ⚠cramping
- ⚠nausea
Larazotide Side Effects
- ⚠headache
- ⚠nausea
- ⚠abdominal discomfort
Research Overview
Motilin
Motilin is a 22-amino-acid peptide released from the upper small intestine and is one of the classic physiologic prokinetic signals. It is a real peptide target for GI motility research, though not commonly used as a standard drug.
Larazotide
Clinical and translational studies suggest larazotide can reduce antigen passage across the epithelium and improve gut barrier function. It is one of the better-known peptides for intestinal permeability and barrier-focused gastrointestinal therapy.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.